|
Daily Medical Update
Non-ulcer dyspepsia
Monday, August 31, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
Neurogastroenterology and motility (2026) - Consensus Statement
Key Findings
- The expert panel reached consensus on recognizing DGBI-induced altered food intake behavior when Rome-criteria gastrointestinal symptoms are worsened by eating, lead to reduced intake, and cause significant unintended weight loss.
- The panel identified organic disease and eating disorders as key differentials, endorsed multidisciplinary management, and reserved enteral or parenteral feeding for life-threatening nutritional deficiency that did not improve after oral approaches failed.
📋 Practice Implication: In dyspepsia with restrictive eating or weight loss, assess nutritional risk and competing diagnoses early and coordinate gastroenterology, nutrition, and behavioral-health care.
|
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (2025) - Practice Guideline
Key Findings
- The panel reached at least 80% agreement on defining epigastric pain syndrome and post-prandial distress syndrome, recommending H. pylori screening with eradication when positive, and advising routine blood tests to exclude systemic disease.
- The panel supported standard-dose PPIs as a short first-line course and concluded that higher PPI doses did not improve response; it discouraged exclusion diets and prokinetics as first-line therapy and recommended tricyclic antidepressants for epigastric pain syndrome and cognitive-behavioral therapy after medical-treatment failure.
📋 Practice Implication: Use the guideline to structure initial evaluation and treatment, reserving endoscopy for age 45 or older, alarm features, or refractory symptoms and matching later therapy to the symptom phenotype.
|
Journal of neurogastroenterology and motility (2026) - Review
Key Findings
- Across the reviewed evidence, P-CABs provided rapid, sustained acid suppression and improved healing or maintenance-remission rates compared with PPIs in erosive reflux disease, particularly severe disease.
- For functional dyspepsia, tegoprazan was reported to improve symptoms without delaying gastric emptying; the review noted limited clinical and real-world data and called for surveillance of long-term hypergastrinemia and mucosal changes.
📋 Practice Implication: Consider a P-CAB selectively when acid-mediated symptoms remain problematic, while recognizing that functional-dyspepsia evidence is less mature than the reflux evidence and requires long-term safety vigilance.
|
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (2025) - Meta-Analysis
Key Findings
- Across 15 randomized trials involving 1,359 patients, exercise therapy improved functional-dyspepsia symptoms, including epigastric fullness and pain.
- Exercise also improved quality of life and sleep and reduced depression, with no serious adverse events reported in the included trials.
📋 Practice Implication: Offer structured exercise as a low-risk adjunct for patients seeking nonpharmacologic symptom management, especially when sleep or mood symptoms coexist.
|
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2026) - Randomized Controlled Trial
Key Findings
- In 69 genotype-preselected participants, nortriptyline did not improve the primary response rate compared with placebo at 12 weeks: 45% versus 58% (P = .276).
- Adverse-event rates did not differ significantly, while nortriptyline plasma levels were higher in responders and treatment belief was associated with improved response (77% vs 36%).
📋 Practice Implication: Do not assume CYP2D6-guided nortriptyline improves dyspepsia outcomes; if a TCA is used, discuss uncertain efficacy and monitor response rather than relying on genotype selection alone.
|
|
💡
Summary
The validated candidates support five high-significance findings spanning multidisciplinary assessment, diagnostic standardization, exercise, genotype-guided nortriptyline, and acid suppression. The strongest treatment signals are for exercise, while the nortriptyline trial was negative versus placebo and the P-CAB evidence remains review-level with limited functional-dyspepsia data.
|
|